All IndicationsGastroenterology
🩺
Pseudomonas Aeruginosa Infection
1
Companies
1
Drug Programs
1
Phase 3
0
Upcoming PDUFAs
Competitors
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| INSM Insmed Incorporated | Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. | Phase 3 | — | — | — |
Development Stage Distribution
Phase 3
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.